BioAge Labs (NASDAQ:BIOA) Shares Gap Down – Time to Sell?

BioAge Labs, Inc. (NASDAQ:BIOA) gapped down before the market opened on Wednesday . The stock had previously closed at $21.32, but opened at $20.13. BioAge Labs shares last traded at $21.0340, with a volume of 218,161 shares.

Analyst Ratings Changes

A number of research firms recently issued reports on BIOA. Weiss Ratings restated a “sell (d-)” rating on shares of BioAge Labs in a report on Thursday, October 30th. Citigroup lifted their price target on shares of BioAge Labs from $10.00 to $15.00 and gave the stock a “buy” rating in a report on Wednesday, October 29th. Finally, Wall Street Zen raised BioAge Labs from a “sell” rating to a “hold” rating in a research report on Sunday. One research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, BioAge Labs presently has a consensus rating of “Hold” and an average target price of $15.00.

BioAge Labs Price Performance

The stock has a market capitalization of $712.19 million, a P/E ratio of -13.13 and a beta of 1.38. The stock has a fifty day moving average price of $12.74 and a 200 day moving average price of $7.92.

BioAge Labs (NASDAQ:BIOA) last issued its quarterly earnings data on Thursday, November 6th. The company reported ($0.56) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.67) by $0.11. The company had revenue of $2.05 million for the quarter.

Insider Transactions at BioAge Labs

In other BioAge Labs news, CFO Dov A. Md Goldstein sold 27,000 shares of the stock in a transaction that occurred on Tuesday, January 13th. The shares were sold at an average price of $19.70, for a total value of $531,900.00. Following the sale, the chief financial officer directly owned 22,408 shares in the company, valued at $441,437.60. This represents a 54.65% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO Kristen Fortney sold 233,107 shares of the firm’s stock in a transaction on Tuesday, January 13th. The shares were sold at an average price of $18.12, for a total transaction of $4,223,898.84. Following the completion of the transaction, the chief executive officer directly owned 976,949 shares of the company’s stock, valued at approximately $17,702,315.88. The trade was a 19.26% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders have sold 347,004 shares of company stock valued at $5,673,859. 20.82% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On BioAge Labs

Institutional investors and hedge funds have recently made changes to their positions in the business. Russell Investments Group Ltd. purchased a new position in BioAge Labs in the 3rd quarter worth $27,000. Police & Firemen s Retirement System of New Jersey purchased a new position in BioAge Labs in the 2nd quarter worth approximately $27,000. Nisa Investment Advisors LLC lifted its position in BioAge Labs by 4,219.4% in the fourth quarter. Nisa Investment Advisors LLC now owns 10,237 shares of the company’s stock valued at $135,000 after purchasing an additional 10,000 shares during the last quarter. Bank of America Corp DE boosted its stake in shares of BioAge Labs by 46.3% during the third quarter. Bank of America Corp DE now owns 11,119 shares of the company’s stock valued at $65,000 after purchasing an additional 3,517 shares during the period. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its holdings in shares of BioAge Labs by 85.6% in the second quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 12,955 shares of the company’s stock worth $54,000 after purchasing an additional 5,976 shares during the last quarter.

BioAge Labs Company Profile

BioAge Labs (NASDAQ: BIOA) is a clinical-stage biotechnology company focused on discovering and developing therapies that address age-associated diseases. The company leverages its proprietary analytics platform to mine large-scale human biological data for insights into the molecular mechanisms of aging. By targeting fundamental aging pathways, BioAge aims to create interventions that extend healthspan and treat conditions that disproportionately affect older populations.

At the core of BioAge’s operations is its integrated drug discovery platform, which combines human omics datasets, machine learning algorithms and experimental validation to identify novel drug targets.